To prepare the sample for cryo-EM study, 4 μL S6P complexed with the N9 Fab (0.7 mg/mL) and 4 μL BD-368-2/BD-604 Fabs (both at 1.0 mg/mL) were mixed, and then immediately applied onto the glow-discharged holy-carbon gold grids (Quantifoil, R1.2/1.3) using an FEI Vitrobot IV. The grids were flash-cooled in liquid ethane and screened using a 200 kV Talos Arctica. The grids were then transferred to a Titan Krios operated at 300 kV for data collection. Movies were recorded on a K2 Summit direct electron detector (Gatan) using the SerialEM software. 32 A total of 4442 movies were recorded for image processing. MotionCor2 33 was used to align and average raw movie frames into motion-corrected images. The CTFFIND4 34 was used to estimate the contrast transfer function (CTF) parameters of each motion-corrected image. The best 3957 micrographs were manually selected and processed by RELION-3.1. 35 The cryo-EM map of BD-368-2 Fab in complex with S6P (EMDB ID: EMD-30374) was used as a reference for the 3D classification (Supplementary information, Table S5). Siu AL, Bibbins-Domingo K, Grossman DC, et al. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(13):1372-1377. A) If the potential F reorganization or a step thereof qualifies as a reorganization or part of a reorganization under another provision of section 368(a)(1), and if a corporation in control (within the meaning of section 368(c)) of the resulting corporation is a party to such other reorganization (within the meaning of section 368(b)), the potential F reorganization will not qualify as a reorganization under section 368(a)(1)(F). Biotinylated proteins were then conjugated to Biolegend TotalSeq™ PE or APC streptavidin oligos at a 5:1 molar ratio of antigen protein to PE/APC streptavidin oligos. The amount of antigen was chosen based on a fixed amount of 0.6 µg PE or APC streptavidin oligos. The antigen protein and streptavidin oligos were mixed and incubated on ice for 30 min. After incubation, antigen-streptavidin oligos were diluted to a final volume of 10 µL. Antigen-streptavidin oligo diluent was then centrifuged at 14,000 × g at 2–8 °C for 10 min. Nine microliter liquid was carefully pipetted out avoiding the bottom of the tube and transferred to a new tube. Antigen-streptavidin oligos were then used immediately for cell staining. 1 × 10 9 antigen-streptavidin oligos were used in every 1 × 10 6 cells in 100 µL.

Guidelines for the implementation of the framework for consolidated financial reporting (FINREP) – Revision 1 (2007) Regulatory Technical Standards on the criteria to identify material risk takers under the Investment Firms Directive (IFD) Regulatory Technical Standards to specify the adjustment of own funds requirements and stress testing of issuers of asset-referenced tokens and of e-money tokens under MiCAR

More Resources

Regulatory Technical Standards on performance-related triggers in STS on-balance -sheet securitisations Implementing Technical Standards on currencies with constraints on the availability of liquid assets (amended) Rather than withdrawing the Proposed Net Value Regulations without comment or with a vague explanation, the Government chose to explain its thinking. The manner in which the Government did so is interesting. Specifically, the Government provided the aforementioned list of technical citations to show that courts and the IRS view Section 332 as not applying to liquidations of insolvent corporations. But, rather than provide a similar list of citations with respect to the impact of insolvency on Section 351 and 368 transactions, the Government stated that "current law is sufficient" — despite having expressly stated in the preamble to the Proposed Net Value Regulations that inconsistent authority existed. Seemingly, the law has retained enough ambiguity to justify leaving the proposed regulations outstanding for the past 12 years. It is not clear what has changed — why now, in 2017, the Government believes that "current law is sufficient." Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature 590, 17 (2021). Regulatory Technical Standards on the minimum content of the governance arrangements on the remuneration policy under MiCAR

Implementing Technical Standards on the format, structure, contents list and annual publication date of the supervisory information to be disclosed by competent authorities under Article 57(4) of IFD Harmonised classification and labelling is a legally binding classification and labelling for a substance, agreed at European Community level. Harmonisation is based on the substance’s physical, toxicological and eco-toxicological hazard assessment.Effective/applicability dates. This paragraph (k) applies to transactions occurring on or after May 9, 2008, except that it does not apply to any transaction occurring pursuant to a written agreement which is binding before May 9, 2008, and at all times after that. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021). Please note: Precautionary measures and guidance on safe use concern the use and handling of the specific substance as such, not of the presence of the substance in other articles or mixtures. The precautionary measures and guidance on safe use are as submitted to ECHA by registrants under the REACH Regulation. Information on precautionary measures and the safe use is submitted by the registrant of a substance and the registrant is solely responsible for its accuracy and completeness. g) The term plan of reorganization has reference to a consummated transaction specifically defined as a reorganization under section 368(a). The term is not to be construed as broadening the definition of reorganization as set forth in section 368(a), but is to be taken as limiting the nonrecognition of gain or loss to such exchanges or distributions as are directly a part of the transaction specifically described as a reorganization in section 368(a). Moreover, the transaction, or series of transactions, embraced in a plan of reorganization must not only come within the specific language of section 368(a), but the readjustments involved in the exchanges or distributions effected in the consummation thereof must be undertaken for reasons germane to the continuance of the business of a corporation a party to the reorganization. Section 368(a) contemplates genuine corporate reorganizations which are designed to effect a readjustment of continuing interests under modified corporate forms. Regulatory Technical Standards on the implementation of group wide AML/CFT policies in third countries

Part or all of the assets of the acquired corporation, the acquiring corporation, or the surviving corporation, as the case may be; Non-application of continuity of interest and continuity of business enterprise requirements. A continuity of the business enterprise and a continuity of interest are not required for a potential F reorganization to qualify as a reorganization under section 368(a)(1)(F). See § 1.368–1(b). Regulatory Technical Standards on the definition of materiality thresholds for specific risk in the trading book RBD and NTD mutations carried by 501Y.V2 abolish a large proportion of neutralizing activity of NAbs elicited in convalescents and vaccineesImplementing Technical Standards Amending Regulation (EU) No 680/2014 on Supervisory Reporting of institutions with regard to prudent valuation iii) This paragraph (d)(4) applies to transactions occurring after December 31, 1999, unless the transaction occurs pursuant to a written agreement that is (subject to customary conditions) binding on that date and at all times thereafter.

A) Disregarded entity. A disregarded entity is a business entity (as defined in § 301.7701–2(a) of this chapter) that is disregarded as an entity separate from its owner for Federal income tax purposes. Examples of disregarded entities include a domestic single member limited liability company that does not elect to be classified as a corporation for Federal income tax purposes, a corporation (as defined in § 301.7701–2(b) of this chapter) that is a qualified REIT subsidiary (within the meaning of section 856(i)(2)), and a corporation that is a qualified subchapter S subsidiary (within the meaning of section 1361(b)(3)(B)). Guidelines on common procedures and methodologies for the supervisory review and evaluation process (SREP) Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Ce Regulatory Technical Standards on pay out in instruments for variable remuneration under the Investment Firms Directive (IFD) Guidelines on criteria for the use of data inputs in the expected shortfall risk measure under the IMA

ii) Except as provided in paragraph (k) of this section, the controlling corporation must control the surviving corporation immediately after the transaction. v) Resulting corporation is the only acquiring corporation. Immediately after the potential F reorganization, no corporation other than the resulting corporation may hold property that was held by the transferor corporation immediately before the potential F reorganization, if such other corporation would, as a result, succeed to and take into account the items of the transferor corporation described in section 381(c). Regulatory Technical Standards on classes of instruments that are appropriate to be used for the purposes of variable remuneration Guidelines on harmonised definitions and templates for funding plans of credit institutions (updated)